$ONCY

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Announces Clinical Supply Agreement to Evaluate Pelareorep in Combination with LOQTORZI ® (toripalimab-tpzi) in Squamous Cell Anal Carcinoma Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses

Oncolytics Biotech (ONCY) and Coherus Oncology (CHRS) agreed to study pelareorep with LOQTORZI for squamous cell anal carcinoma. The trial, set for 2027, targets patients who failed first-line treatments. Oncolytics aims to evaluate pelareorep's efficacy with a marketed PD-1 inhibitor. Both companies highlighted the unmet need in this indication.

Oncolytics Biotech presented data at the 68th ASH Annual Meeting showing pelareorep's immune-activating effects in relapsed/refractory multiple myeloma patients, including increased CD80 expression and CD8 effector memory T cells. Clinical responders showed greater immune activity than non-responders, according to the company.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients Single-cell sequencing demonstrates pelareorep’s ability to remodel the tumor microenvironment in a hematological cancer SAN DIEGO, CA, November 9, 2026 – Oncoly

Oncolytics Biotech Inc. (ONCY) reported immune activation findings in multiple myeloma patients from a Phase 1b/2 trial, with data to be presented at ASH on December 12, 2026. The findings show antiviral immune activation and enhanced antitumor immunity with pelareorep, though further clinical results are needed for assessment.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels

Oncolytics Biotech (ONCY) reported data from a study showing pelareorep, its investigational immunotherapy, increased HPV-16-specific T cells and tumor-infiltrating lymphocytes in anal cancer patients. The treatment, combined with a checkpoint inhibitor, led to tumor shrinkage in four patients, including two complete responses. The Phase 1/2 study is evaluating the safety and efficacy of the combination therapy in unresectable anal cancer patients.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results fo

Oncolytics Biotech reported updated data from its GOBLET study, showing that pelareorep combined with atezolizumab achieved a median response duration of 15 months in anal cancer patients, exceeding historical results. All responding patients survived beyond 12 months, with some living over 24 months. The company plans to pursue registration and expand into HPV-driven head and neck cancer, supported by FDA Fast Track Designation.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer Study launched earlier this year is expected to confirm previous efficacy signal in 2L KRAS-mutant MSS colorectal cancer study that saw 17 months PFS